BioNTech SE

BATS-CHIXE:22UAD Stock Report

Market Cap: €20.0b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BioNTech Valuation

Is 22UAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 22UAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 22UAD's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 22UAD's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 22UAD?

Key metric: As 22UAD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 22UAD. This is calculated by dividing 22UAD's market cap by their current revenue.
What is 22UAD's PS Ratio?
PS Ratio7.1x
Sales€2.81b
Market Cap€20.02b

Price to Sales Ratio vs Peers

How does 22UAD's PS Ratio compare to its peers?

The above table shows the PS ratio for 22UAD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.6x
GNS Genus
2.1x2.59%UK£1.4b
OXB Oxford Biomedica
4.3x18.99%UK£740.0m
SCLP Scancell Holdings
45.2x-55.26%UK£230.9m
HLN Haleon
2.7x3.96%UK£29.7b
22UAD BioNTech
7.1x-2.90%€23.3b

Price-To-Sales vs Peers: 22UAD is good value based on its Price-To-Sales Ratio (7.1x) compared to the peer average (14.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 22UAD's PS Ratio compare vs other companies in the GB Biotechs Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
2.1x2.59%US$1.86b
OXB Oxford Biomedica
4.3x18.99%US$990.94m
0KF3 Palatin Technologies
2x-49.85%US$24.91m
SBTX SkinBioTherapeutics
3.5x30.43%US$26.90m
No. of Companies10PS020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 22UAD is good value based on its Price-To-Sales Ratio (7.1x) compared to the European Biotechs industry average (8.6x).

Price to Sales Ratio vs Fair Ratio

What is 22UAD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

22UAD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 22UAD's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 22UAD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€105.65
0%
16.86%€134.76€65.11n/a19
Jun ’27n/a
€105.65
0%
16.86%€134.76€65.11n/a19
May ’27n/a
€111.63
0%
17.94%€148.43€64.41n/a18
Apr ’27€74.65
€113.72
+52.34%
17.06%€148.43€65.67n/a18
Mar ’27€93.00
€118.23
+27.13%
12.09%€148.79€87.12n/a19
Feb ’27€99.40
€118.43
+19.15%
12.04%€148.79€87.12n/a19
Jan ’27€80.25
€118.03
+47.07%
12.73%€148.79€87.12n/a19
Dec ’26€86.30
€118.08
+36.82%
12.68%€148.79€87.12n/a19
Nov ’26n/a
€115.76
0%
12.54%€147.88€84.97n/a20
Oct ’26€84.50
€116.09
+37.38%
12.51%€147.69€84.97n/a20
Sep ’26€86.20
€117.56
+36.38%
10.95%€147.69€95.96n/a20
Aug ’26€92.05
€118.02
+28.21%
12.69%€149.41€96.18n/a20
Jul ’26€91.25
€116.79
+27.99%
15.32%€149.41€72.41n/a21
Jun ’26€83.70
€115.90
+38.47%
15.16%€150.70€72.41n/a22
May ’26€90.40
€123.13
+36.20%
12.86%€157.59€98.49n/a20
Apr ’26€84.45
€127.09
+50.49%
11.66%€157.59€101.55€74.6521
Mar ’26n/a
€134.39
0%
11.81%€166.54€114.26€93.0020
Feb ’26n/a
€133.87
0%
12.13%€167.08€114.26€99.4020
Jan ’26n/a
€131.19
0%
10.85%€163.73€115.45€80.2519
Dec ’25n/a
€129.54
0%
9.64%€163.73€115.56€86.3018
Nov ’25n/a
€119.08
0%
17.13%€157.49€82.32n/a18
Oct ’25n/a
€111.39
0%
19.60%€153.73€76.42€84.5018
Sep ’25n/a
€99.20
0%
20.43%€155.58€77.33€86.2018
Aug ’25n/a
€103.43
0%
20.32%€158.55€83.53€92.0518
Jul ’25n/a
€103.54
0%
20.23%€159.58€83.53€91.2518
Jun ’25n/a
€103.10
0%
20.40%€158.71€83.26€83.7018
€106.13
Fair Value
24.9% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 13:34
End of Day Share Price 2026/05/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 31 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harry GillisBerenberg
Zhiqiang ShuBerenberg
Samuel EnglandBerenberg